Compounds > ceftizoxime alapivoxil
Page last updated: 2024-11-11

ceftizoxime alapivoxil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

ceftizoxime alapivoxil: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID53394888
MeSH IDM0336983

Synonyms (9)

Synonym
ceftizoxime alapivoxil
FT-0659697
2,2-dimethylpropanoyloxymethyl 7-[[2-[2-(2-azanylpropanoylamino)-1,3-thiazol-4-yl]-2-methoxyimino-ethanoyl]amino]-8-oxidanylidene-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
A806994
7-[[2-[2-[(2-amino-1-oxopropyl)amino]-4-thiazolyl]-2-methoxyimino-1-oxoethyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid (2,2-dimethyl-1-oxopropoxy)methyl ester
135821-54-4
BCP28430
[(2,2-dimethylpropanoyl)oxy]methyl 7-{2-[2-(alanylamino)-1,3-thiazol-4-yl](methoxyimino)acetamido}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
DTXSID30869849

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" However, there were no significant differences in pharmacokinetic parameters including T(max), cumulative urinary excretion rates of CTIZ and cumulative urinary excretion rates of pivaloylcarnitine for 12 h after the dosing between the pretreated and control groups."( Effects of gastrointestinal stimulant and suppressant pretreatment on the pharmacokinetics of AS-924, a novel ester-type cephem antibiotic.
Kano, T; Kitamura, T; Mori, N; Sakai, A; Shimada, J; Sugihara, T; Yamaji, S; Yanagawa, A; Yano, K, 2001)		0.31

Bioavailability

ExcerptReferenceRelevance
" Among these prodrugs, pivaloyloxymethyl 7beta-[(Z)-2-(2-(S)-alanylaminothiazol-4-yl)-2-methoxyiminoa cetamido]-3-cephem-4-carboxylate hydrochloride (ceftizoxime alapivoxil, AS-924) was well absorbed after oral administration in experimental animals and showed potent therapeutic effects in mice infected with gram-positive and gram-negative bacteria."( AS-924, a novel bifunctional prodrug of ceftizoxime.
Hatano, S; Kakeya, N; Kasai, M; Kitagawa, M; Nishimura, K; Shirahase, H; Yoshimi, A, 1999)		0.3
" This novel prodrug, produced by esterifying CTIZ with a lipophilic pivaloyloxymethyl (POM) group and introducing a water soluble L-alanyl group, is expected to increase the bioavailability and thereby, augment the antibacterial activity of CTIZ in vivo compared with existing prodrugs."( AS-924, a novel, orally active, bifunctional prodrug of ceftizoxime: physicochemical properties, oral absorption in animals, and antibacterial activity.
Aoki, A; Hatano, S; Kasai, M; Kitagawa, M; Kodama, T; Mori, N; Nishijima, T; Nishimura, K; Sakai, A; Sugihara, T; Suzuki, T; Toriya, M; Yamaguchi, S; Yoshimi, A, 2001)		0.31

Dosage Studied

ExcerptRelevanceReference
" To study the effect of the L-alanyl group in AS-924 on its bioavailability, the plasma concentration profiles of CTIZ in dogs were examined following the dosing of AS-924 and CTIZ-POM, in powder form, after pretreatment with the antacid ranitidine, and following the dosing of AS-924 after pretreatment with a gastrointestinal motility stimulant metoclopramide or suppressant scopolamine butylbromide."( AS-924, a novel, orally active, bifunctional prodrug of ceftizoxime: physicochemical properties, oral absorption in animals, and antibacterial activity.
Aoki, A; Hatano, S; Kasai, M; Kitagawa, M; Kodama, T; Mori, N; Nishijima, T; Nishimura, K; Sakai, A; Sugihara, T; Suzuki, T; Toriya, M; Yamaguchi, S; Yoshimi, A, 2001)		0.31
" However, there were no significant differences in pharmacokinetic parameters including T(max), cumulative urinary excretion rates of CTIZ and cumulative urinary excretion rates of pivaloylcarnitine for 12 h after the dosing between the pretreated and control groups."( Effects of gastrointestinal stimulant and suppressant pretreatment on the pharmacokinetics of AS-924, a novel ester-type cephem antibiotic.
Kano, T; Kitamura, T; Mori, N; Sakai, A; Shimada, J; Sugihara, T; Yamaji, S; Yanagawa, A; Yano, K, 2001)		0.31
" These results indicate the need to select drugs and to instruct gastrectomized patients regarding dosage and administration, taking the pharmacokinetics of drugs into consideration."( Pharmacokinetics of cefcapene pivoxil and AS-924 in gastrectomized patients.
Fujimoto, M, 2001)		0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (25.00)18.2507
2000's6 (75.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (12.50%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
domperidone
Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.. domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.		3.3911benzimidazoles;
heteroarylpiperidine		antiemetic;
dopaminergic antagonist
cephalosporin c
cephalosporin C: RN given refers to parent cpd; structure in Merck, 9th ed, #1937. cephalosporin C : A cephalosporin antibiotic carrying a 3-acetoxymethyl substituent and a 6-oxo-N(6)-L-lysino group at position 7.		2.9240cephalosporinfungal metabolite
ranitidine
Ranitidine: A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers.. ranitidine : A member of the class of furans used to treat peptic ulcer disease (PUD) and gastroesophageal reflux disease.		210C-nitro compound;
furans;
organic sulfide;
tertiary amino compound		anti-ulcer drug;
drug allergen;
environmental contaminant;
H2-receptor antagonist;
xenobiotic
s 1108
S 1108: structure given in first source; an oral cephem antibiotic and prodrug of S-1006		210
cefteram pivoxil
cefteram pivoxil: structure given in first source		2.41201,3-thiazoles;
cephams;
oxime O-ether;
pivaloyloxymethyl ester;
tetrazoles
butylscopolammonium bromide
Butylscopolammonium Bromide: Antimuscarinic quaternary ammonium derivative of scopolamine used to treat cramps in gastrointestinal, urinary, uterine, and biliary tracts, and to facilitate radiologic visualization of the gastrointestinal tract.		3.3911
cefmenoxime
Cefmenoxime: A cephalosporin antibiotic that is administered intravenously or intramuscularly. It is active against most common gram-positive and gram-negative microorganisms, is a potent inhibitor of Enterobacteriaceae, and is highly resistant to hydrolysis by beta-lactamases. The drug has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.. cefmenoxime : A third-generation cephalosporin antibiotic, bearing a 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino group at the 7beta-position and a [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl group at the 3-position.		2.4120cephalosporinantibacterial drug
ConditionIndicatedRelationship StrengthStudiesTrials
Bacterial Infections, Gram-Negative
[description not available]		0210
Bacterial Infections, Gram-Positive
[description not available]		0210
Gram-Negative Bacterial Infections
Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.		0210
Gram-Positive Bacterial Infections
Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method.		0210
Cancer of Stomach
[description not available]		0210
Stomach Neoplasms
Tumors or cancer of the STOMACH.		0210